Site search
2811 results for '' found
Integrative approaches for Optimizing Recognition, Management and Education of concussion at the community sports level (ACTRN12623000554662)
Integrative approaches for Optimizing Recognition, Management and Education of concussion at the community sports level (ACTRN12623000554662)
/research/clinical-trials/alfred-clinical-trials/integrative-approaches-for-optimizing-recognition-management-and-education-of-concussion-at-the-community-sports-level-actrn12623000554662
The role of pharmacological heart failure therapy in LV recovery following INDEX catheter ablation for atrial fibrillation [AF] induced cardiomyopathy - the INDEX-AF Study (Registration Pending)
The role of pharmacological heart failure therapy in LV recovery following INDEX catheter ablation for atrial fibrillation [AF] induced cardiomyopathy - the INDEX-AF Study (Registration Pending)
/research/clinical-trials/alfred-clinical-trials/the-role-of-pharmacological-heart-failure-therapy-in-lv-recovery-following-index-catheter-ablation-for-atrial-fibrillation-af-induced-cardiomyopathy-the-index-af-study-registration-pending
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Conc
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Conc
/research/clinical-trials/alfred-clinical-trials/a-phase-3-double-blind-randomized-study-to-compare-the-efficacy-and-safety-of-luspatercept-ace-536-versus-placebo-in-subjects-with-myeloproliferative-neoplasm-associated-myelofibrosis-on-conc
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis (NCT05764161)
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis (NCT05764161)
/research/clinical-trials/alfred-clinical-trials/a-phase-3-double-blind-randomized-vehicle-controlled-efficacy-and-safety-study-of-ruxolitinib-cream-in-participants-with-prurigo-nodularis-nct05764161
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)
/research/clinical-trials/alfred-clinical-trials/a-phase-1-open-label-multicenter-study-of-incb161734-in-participants-with-advanced-or-metastatic-solid-tumors-with-kras-g12d-mutation-nct06179160
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Add
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Add
/research/clinical-trials/alfred-clinical-trials/a-phase-3-randomized-double-blind-placebo-controlled-multicenter-study-to-evaluate-the-efficacy-and-safety-of-tafasitamab-plus-lenalidomide-in-addition-to-rituximab-versus-lenalidomide-in-add
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in patients with Pulmonary Arterial
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in patients with Pulmonary Arterial
/research/clinical-trials/alfred-clinical-trials/impahct-a-phase-2b-3-randomized-double-blind-placebo-controlled-24-week-dose-ranging-and-confirmatory-study-to-evaluate-the-safety-and-efficacy-of-av-101-in-patients-with-pulmonary-arterial
An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-neg
An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-neg
/research/clinical-trials/alfred-clinical-trials/an-open-label-study-evaluating-the-safety-antiviral-activity-and-pharmacokinetics-of-imc-i109v-in-hla-a-0201-positive-patients-with-chronic-hbv-who-are-non-cirrhotic-hepatitis-b-e-antigen-neg
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-P
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-P
/research/clinical-trials/alfred-clinical-trials/a-phase-1-2-first-in-human-study-of-the-safety-and-efficacy-of-imc-f106c-as-a-single-agent-and-in-combination-with-checkpoint-inhibitors-in-hla-a-0201-positive-participants-with-advanced-prame-p
A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (NCT04291885)
A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (NCT04291885)
/research/clinical-trials/alfred-clinical-trials/a-randomised-placebo-controlled-phase-ii-trial-of-adjuvant-avelumab-in-patients-with-stage-i-iii-merkel-cell-carcinoma-nct04291885